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Natriuretic Peptides
Renal Protective After All?*
Guido Boerrigter, MD, John C. Burnett, JR, MD
Rochester, Minnesota
Renal dysfunction has emerged as an important indepen-
dent predictor of adverse outcomes, renal as well as cardio-
vascular. Renal function is crucially affected by intrinsic
renal factors (particularly remaining functional renal mass),
hemodynamic function (renal perfusion pressure, renal ve-
nous pressure), oxygen delivery, and neurohumoral input.
The natriuretic peptides play an important role in cardio-
vascular homeostasis. The 28-amino acid atrial natriuretic
peptide (ANP) and 32-amino acid B-type natriuretic pep-
tide (BNP1–32) are secreted by the heart in response to
ardiac stretch and stress. By activating guanylyl cyclase A
GC-A), they exert their pleiotropic actions, which include
atriuresis, vasodilation, suppression of renin, angiotensin
I, and aldosterone as well as antihypertrophic, antifibrotic,
ascular regenerative, and cytoprotective properties (1,2).
iven this background, it is no surprise that clinical trials
ave tested the therapeutic benefit of administering exoge-
ous ANP (approved in Japan as carperitide) and BNP1–32
(approved in the U.S. as nesiritide) in a variety of cardio-
vascular disease states. That has led to at times promising,
neutral, or disconcerting results as it relates to overall benefit
and renal function (3–9).
See page 897
Sezai et al. (10) in the NU-HIT for CKD trial in this
issue of the Journal tested the renal effects of carperitide
infused during and after coronary artery bypass graft surgery
(CABG) with cardiopulmonary bypass (CPB) in patients
(n  285) with pre-operative chronic kidney disease
CKD), defined as estimated glomerular filtration rate
eGFR) 60 ml·min1·1.73 m2. Carperitide was initiated
at the start of bypass at 0.2 g·kg1·min1, reduced to 0.1
g·kg1·min1 at the beginning of oral medication, and
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has licensed cenderitide to Nile Therapeutics.discontinued 12 h thereafter. These investigators report that
creatinine levels were lower with carperitide compared to
placebo on the first day after surgery, and this effect was still
present 1 year later. The same was true for aldosterone until
1 month after surgery. Although there was no significant
difference in mortality at 1 year, the study was probably not
powered for this endpoint. Fewer patients in the carperitide
group had a cardiac event, and, importantly, fewer required
dialysis.
This study complements 2 similar studies by the same
authors with carperitide during and after CPB. In the first,
in patients with normal eGFR and left ventricular (LV)
function (n  504), carperitide decreased creatinine com-
pared to placebo during the 7-day post-operative observa-
tion period, and reduced the length of hospital stay (8).
However, given the small number of events in this healthier
group of patients, carperitide did not significantly reduce
mortality (1.6% vs. 2.4%) or the need for dialysis (0% vs.
1.6%). In the other study, patients (n  133) were enrolled
with LV dysfunction defined as ejection fraction 35% (9).
Carperitide decreased creatinine and increased LV ejection
fraction compared to placebo for at least a year after surgery,
and reduced perioperative complications and hospital length
of stay. While all-cause mortality showed no difference, the
carperitide group had fewer cardiac events.
Mentzer et al. (5) reported the results of an exploratory
randomized trial with nesiritide, the NAPA (Nesiritide
Administered Peri-Anesthesia in Patients Undergoing Car-
diac Surgery) trial (n  279) in patients undergoing CPB.
Compared to placebo, nesiritide (0.01 g·kg1·min1, no
bolus) improved renal function, increased urine output,
shortened hospital length of stay, and reduced 180-day
mortality. Ejaz et al. (7) compared a 5-day infusion of
nesiritide to placebo in patients (n  94) undergoing
high-risk cardiac surgery, in 77% for thoracic aortic aneu-
rysm. Although nesiritide reduced creatinine compared to
placebo, there were no differences between groups regarding
need for dialysis, all-cause mortality, or both at 30 days.
Likewise, the hospital length of stay was similar. Of note,
per protocol, the dose of nesiritide was to be increased from
0.01 to 0.03 g/kg to maintain post-operative urine output
1 ml·kg1·h1. This algorithm was probably the reason
for a significantly increased use of vasopressors in the
nesiritide group, and may conceivably have offset some
potential benefit of nesiritide therapy. In a small proof of
concept trial, we defined the actions of low-dose nesiritide
(0.05 ng·kg1·min1) infused for 24 h started at the time of
anesthesia in a double-blind placebo-controlled trial of
patients with CKD (eGFR 60 ml/min/1.73 m2) under-
oing CPB surgery with a focus on cystatin C and aldoste-
one. We observed a significant decrease in cystatin C with
esiritide compared to placebo and a lowering of aldoste-
one (6). Taken together, GC-A agonism with both ANP
nd BNP have shown promising beneficial results in pa-
ients undergoing CPB surgery.
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pic actions of GC-A agonists, these are likely multifactorial
and include suppression of neurohormones such as aldoste-
rone, angiotensin II, and the sympathetic nervous system.
Another mechanism could be an improved post-operative
LV ejection fraction as was seen in patients with pre-
operative LV dysfunction indicated above (9). In addition,
GC-A activation may have improved renal perfusion and
promoted cell survival, thus inhibiting the loss of functional
renal tissue. In future studies, assessment of kidney injury
markers, such as NGAL and KIM-1, may help to identify
whether GC-A activation indeed reduces kidney injury.
Most recently at the 2011 meeting of the American Heart
Association, the results of a key 7,000-patient clinical trial
using nesiritide for acute decompensated heart failure
(ADHF) were announced and have relevance to the use of
natriuretic peptides as therapeutic agents for cardiorenal
disease. This trial, ASCEND (Acute Study of Clinical
Effectiveness of Nesiritide in Decompensated Heart Fail-
ure) (11), was conducted after safety concerns were raised
regarding renal function and mortality on the basis of
publicly available information on earlier trials with nesiritide
for HF (3,4). The ASCEND trial showed that nesiritide for
patients with ADHF was safe and, specifically, did not
harm renal function. However, it also did not improve
survival or reduce rehospitalization and only tended to
improve symptomatic status (11). Nesiritide was infused at
0.01 g·kg1·min1; an initial 2 g/kg bolus could be given
at the discretion of the investigator, which was the case in
approximately 62% of patients. Of note, asymptomatic and
symptomatic hypotension occurred more often with nesirit-
ide (21.4% vs. 12.4% and 7.1% vs. 4.0%, respectively).
While the demonstration of safety is reassuring, it remains
to be seen whether specific groups of acute HF patients can
be identified that derive clinically significant benefit from
nesiritide.
Many more questions remain regarding GC-A agonists
as therapeutic agents that need to be addressed in future
studies. For example:
1. An important question is whether there are relevant
clinical differences between carperitide and nesiritide, for
example, as it relates to the incidence and duration of
hypotension.
2. Degradation of NPs to an inactive metabolite is probably
a multistep process, and some intermediate NP deriva-
tives are likely to have a shorter half-life while still
retaining bioactivity. Would it be safer to administer
such a NP derivative with short half-life to patients with
ADHF so that any developing hypotension would be less
sustained? Do any of these endogenous NP derivatives
have an activity profile that may be more appropriate for
patients in critical hemodynamic condition (12)? For
example, BNP3–32, a BNP derivative reported to circu-
late at higher concentrations than BNP1–32, levels in HF
patients was natriuretic but not hypotensive in healthy
canines (13).. Can we modulate the activity of GC-A agonists by
combining them with inhibitors of their degradation,
e.g., neprilysin inhibitors? Also, can we combine GC-A
agonists with phosphodiesterase inhibitors to reduce
degradation of the NP’s second messenger cGMP?
. Should we also target GC-B, the receptor of C-type
natriuretic peptide, which has important vascular and
renal actions especially at the level of the podocyte (14)?
Indeed, the use of a novel dual GC-A and GC-B agonist
(cenderitide) designed by our group, which is currently in
clinical trials, could have an important role in renopro-
tection in CPB surgery on the basis of such novel
properties.
. In the case of ADHF, would chronic therapy with NPs
after hospital discharge improve survival and reduce
rehospitalizations? This strategy is currently being pur-
sued. Specifically, chronic subcutaneous delivery of the
above-mentioned cenderitide is being evaluated using
the same pump technology used for the treatment of
diabetes mellitus.
In summary, Sezai et al. (10) remind us that GC-A
gonism has shown promising cardiorenal protective effects
n several studies, and that it remains an attractive thera-
eutic target worthy of continuing investigation.
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